HC Wainwright reissued their buy rating on shares of Repligen (NASDAQ:RGEN) in a research note published on Tuesday, BenzingaRatingsTable reports. HC Wainwright currently has a $151.00 price target on the biotechnology company’s stock, up from their previous price target of $143.00.
Other research analysts also recently issued research reports about the stock. Craig Hallum lifted their price objective on shares of Repligen from $120.00 to $145.00 and gave the company a buy rating in a research report on Thursday, May 7th. Stifel Nicolaus lifted their price target on Repligen from $135.00 to $150.00 and gave the stock a buy rating in a report on Wednesday, May 27th. SVB Leerink upped their price objective on Repligen from $115.00 to $150.00 and gave the company an outperform rating in a research note on Thursday, May 7th. BidaskClub cut Repligen from a buy rating to a hold rating in a research report on Saturday, June 6th. Finally, ValuEngine lowered Repligen from a buy rating to a hold rating in a report on Friday, May 1st. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $131.71.
Shares of NASDAQ RGEN opened at $123.61 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 14.09 and a current ratio of 15.56. The stock has a 50 day moving average price of $125.51 and a 200 day moving average price of $105.58. The stock has a market capitalization of $6.09 billion, a PE ratio of 274.69, a price-to-earnings-growth ratio of 4.70 and a beta of 1.07. Repligen has a 52 week low of $72.32 and a 52 week high of $143.93.
Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.22 by $0.10. Repligen had a return on equity of 5.55% and a net margin of 8.11%. The company had revenue of $76.09 million during the quarter, compared to the consensus estimate of $71.79 million. During the same quarter in the prior year, the firm posted $0.28 EPS. The firm’s revenue for the quarter was up 25.5% compared to the same quarter last year. As a group, research analysts forecast that Repligen will post 1.13 EPS for the current year.
In related news, CEO Anthony Hunt sold 46,953 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $139.77, for a total transaction of $6,562,620.81. Following the transaction, the chief executive officer now directly owns 238,157 shares of the company’s stock, valued at $33,287,203.89. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Nicolas Barthelemy sold 2,688 shares of Repligen stock in a transaction dated Friday, April 3rd. The stock was sold at an average price of $99.99, for a total transaction of $268,773.12. Following the completion of the sale, the director now owns 6,761 shares of the company’s stock, valued at approximately $676,032.39. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,840 shares of company stock worth $14,008,263. 1.50% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its position in shares of Repligen by 2.1% in the first quarter. State Street Corp now owns 1,588,648 shares of the biotechnology company’s stock valued at $153,368,000 after buying an additional 32,598 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Repligen by 6.1% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,342,839 shares of the biotechnology company’s stock worth $129,638,000 after acquiring an additional 77,505 shares during the period. 12 West Capital Management LP raised its holdings in Repligen by 18.6% in the 4th quarter. 12 West Capital Management LP now owns 1,178,524 shares of the biotechnology company’s stock valued at $109,013,000 after acquiring an additional 185,000 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Repligen by 497.4% during the 1st quarter. Alliancebernstein L.P. now owns 981,043 shares of the biotechnology company’s stock valued at $94,710,000 after acquiring an additional 816,822 shares during the period. Finally, Macquarie Group Ltd. grew its holdings in shares of Repligen by 10.4% during the 4th quarter. Macquarie Group Ltd. now owns 965,962 shares of the biotechnology company’s stock worth $89,351,000 after purchasing an additional 91,083 shares in the last quarter. 89.18% of the stock is currently owned by institutional investors.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: NASDAQ
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.